Atrys receives public funding for four R&D projects
November 26, 2015
Atrys has received funding for four new R&D projects in the RETOS' call 2015. The execution period of which will begin in June 2015 and end in May 2018.
The finances projects are:
GLIOMATHETAPY - IMMUNOTHERAPY WITH A MONOCLONAL ANTIBODY IN HIGH GRADE BRAIN TUMORS.
The overall objective of this project is to determine the therapeutic potential of the monoclonal antibody Nilo 1 for the treatment of human high-grade brain tumors, either as monotherapy or in combination with other genotoxic agents.
Nile 1 monoclonal antibody has been generated to against surface antigens of mouse neurosphere cells, and recognizes mouse neural stem cells (type B astrocytes), both in physiological and pathological conditions. Moreover, recent experiments have shown that Nilo1 recognizes a subpopulation of cells in human adult malignant gliomas, being capable of in vitro inhibiting the proliferation of neurospheres.
In order to determine their therapeutic potential in human high-grade brain tumors, its use in the diagnosis of human brain tumors will be validated, the inhibition potential will be tested in human brain tumorespheres and its therapeutic effect will be assessed on human tumor xenografts in mice.
The project is led by Althia and will be developed jointly with researchers from the CIB-CSIC and the Imdea Institute of Nanoscience.
In addition, Atrys participates in three projects more financed by the program RETOS. The projects are:
PREDICTGYN - DEVELOPMENT OF NEW APPROACHES IN THE INDIVIDUALIZED MANAGEMENT OF PATIENTS WITH GYNECOLOGICAL CANCER
PAPILOMA - NEW RAPID AND HIGH SENSITIVITY DIAGNOSIS FOR HUMAN PAPILOMA VIRUS
ZITOMAB - DEVELOPMENT OF ANTI-TUMOR IMMUNOTHERAPIES OF SECOND GENERATION: ANTIBODIES AND NANOBODIES CONJUGATED WITH TOXINS OF SPECIFIC FORM THROUGH INTEIN-ZIP
Detailed information on each project can be found in the R&D section, Research Projects.